Zoetis (ZTS)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-07
$76.29+1.15%
Close 2026-07-07 · 1-day change
Reading ZTS? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ZTS free→NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-07
Reading ZTS? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ZTS free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on long-term growth through product approvals and international expansion. The current thesis state is intact, supported by strong recent financial performance, though management execution has been volatile.
The market currently prices ZTS as cheap compared to its peers, reflecting a low expectations gap. There is a sense of fragility due to weak execution quality, but the overall valuation appears justified given the company's recent performance.
Fundamentals are likely to show continued growth in international revenue, which increased by 17% recently. However, the overall revenue growth remains modest, and there are concerns about cost management as operating income has decreased.
The long-term thesis hinges on the company's ability to drive revenue growth through new product approvals and maintain momentum in the healthcare sector. Key factors include the performance of sector bellwethers and the potential for ZTS to meet or exceed guidance in upcoming earnings calls.
In the next 1 to 3 years, ZTS appears to be positioned well, but execution risks and sector performance will be critical to watch. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss raises concerns about future growth. Analysts suggest that stabilization for Zoetis' products could take several quarters. This delay may impact revenue growth and guidance.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: EPS guidance will indicate how profit expectations are changing. This affects how investors view the company's future.
Confirms:Management expects higher EPS for 2026. This is above current forecasts.
Disproves:Management lowers EPS guidance for 2026 or keeps it unchanged.
Why it matters: A worse decline would signal deeper issues in the U.S. market. This could affect overall growth.
Confirms:U.S. segment revenue declines more than 8% compared to the same quarter last year.
Disproves:U.S. segment revenue declines less than or stabilizes around -8%.
Why it matters: Growth in international sales is important for the company. It shows how well Zoetis is doing globally.
Confirms:International segment revenue grows by more than 10% year over year in Q2 2026.
Disproves:International segment revenue growth falls below 5% year over year in Q2 2026.
Why it matters: This would signal continued challenges in the U.S. market and price sensitivity among pet owners.
Confirms:Q2 2026 revenue growth reported below 2% year over year.
Disproves:Q2 2026 revenue growth exceeds 2% year over year.
Why it matters: The revenue growth guidance will show how management plans to boost sales. This is key for investor confidence.
Confirms:Management expects higher revenue growth for 2026. This is above what people thought before.
Disproves:Management lowers revenue growth guidance for 2026 or keeps it unchanged.
Why it matters: The dividend news shows the company is doing well and cares about shareholders.
Confirms one read:Announcement of a dividend increase for Q3 2026.
Confirms the other:Announcement of a dividend cut or suspension for Q3 2026.
Why it matters: This deal could help Zoetis create better products for livestock.
Confirms:Look for an announcement about finishing the Neogen deal by the end of 2026.
Disproves:Watch for news about delays or problems with the Neogen deal.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: New product approvals can drive revenue growth and improve market position. This is key for future performance.
Confirms:At least one new product gets approved from over 12 potential blockbusters.
Disproves:No new product approvals announced within the next quarter.
Why it matters: If sector revenue growth slows, it may impact Zoetis' performance. This could change investor outlook.
Confirms:Sector revenue growth falls below its median rate.
Disproves:Sector revenue growth remains above its median rate.
Why it matters: A drop below this level shows a big slowdown in growth.
Confirms:2026 guidance for organic revenue growth is below 2%.
Disproves:2026 guidance for organic revenue growth stays at or above 2%.
Why it matters: A confirmed dividend shows the company's commitment to returning cash to shareholders. This can boost investor trust.
Confirms:Management confirms the dividend of $0.53 per share will be paid as planned.
Disproves:Management delays or cuts the dividend payment for Q3 2026.
Why it matters: New product approvals are key for boosting revenue and staying a market leader.
Confirms:Announcement of at least one new product approval in the next quarter.
Disproves:No new product approvals announced in the next quarter.
Why it matters: New product approvals can help Zoetis make more money. This is important for staying ahead.
Confirms:Look for at least one new product approval. It should meet a big need in animal health.
Disproves:If there are no new product approvals by the end of 2026, it may mean delays.